The U.S. Food and Drug Administration and the U.S. Drug Enforcement Administration issued joint warning letters to operators of two websites illegally selling Schedule II stimulants, including amphetamine drug products marketed as Adderall. These websites sell Adderall online without a prescription, which places consumers at risk.
The U.S. health regulator approved Marinus Pharmaceuticals Inc.’s lead drug to treat seizures associated with a rare genetic disorder in patients two years of age and older, the company said on March 18, sending its shares soaring around 36 percent.
Walmart Inc. filed a lawsuit against the federal government, seeking clarity on the roles and legal responsibilities of pharmacists and pharmacies in filling opioid prescriptions.
Trump administration resolves fentanyl dispute but congressional support needed for broader crackdownChina, Congress, Department of Health and Human Services (HHS), Donald Trump, Drug Enforcement Administration (DEA), Fentanyl, House of Representatives, Opioids, U.S. Justice Department, United States
The Trump administration has resolved an internal dispute over how to handle new variants of fentanyl that it believes can beef up the fight against the deadly synthetic painkiller without hindering research to ease the opioid crisis, according to a draft agreement seen by Reuters.
The Trump administration said it was proposing that U.S. pharmaceutical companies cut production of the six most abused opioids by 10 percent next year.
The U.S. DEA proposed a 20 percent reduction in the manufacture of certain commonly prescribed opioid painkillers as well as other controlled substances for 2018.
Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter related to its marketed medicines, seeking documents related primarily to its “good […]